Melanoma

The grounding supports melanoma as arising from melanocytic cells and notes that it may originate de novo or from a pigmented nevus or malignant lentigo. It also indicates that genomic alterations in signaling pathways such as MAPK and PI3K contribute to melanoma development and progression. No single external cause is established in the supplied material.

Melanoma progression is linked to dysregulated signaling, especially the RAS/RAF/MAPK cascade and the PI3K pathway, through genomic alterations in pathway components. The disease also involves interactions with the tumor microenvironment and the immune system, including tumor-infiltrating lymphocytes and immune checkpoint pathways. These mechanisms contribute to proliferation, survival, invasion, metastasis, and treatment resistance.

The supplied grounding identifies adult age as the typical demographic and notes that melanoma incidence is rising worldwide. It also indicates that melanoma can arise from a pigmented nevus or malignant lentigo, which are associated precursor lesions. No additional risk factors are supported by the grounding.

Localized early-stage melanoma is generally treated with surgery, and the literature notes that surgery alone can be sufficient in early disease. For advanced or metastatic melanoma, treatment categories include immune checkpoint inhibitors, cytokine therapy such as IL-2, chemotherapy, targeted therapy against the MAPK pathway, and adjuvant therapy in selected settings. The grounding also mentions cancer vaccines and clinical trial enrollment as part of management discussions for higher-risk disease.